The IPO Buzz: Parabilis Therapeutics (PBLS Proposed) Upsizes IPO by 1/3 to $600 Million

Parabilis Therapeutics (PBLS Proposed) upsized its IPO to 33.33 million shares – up from 25 million initially – and keeping the price range at $17.00 to $19.00  - to raise $600 million, if priced at the $18.00 mid-point of its range, according to an S-1/A filing early today – Tuesday, June 9, 2026. The cancer biotech’s IPO is set to price tonight – after the closing bell – to tra..

Read more June 9, 2026

IPO Calendar

Company Symbol proposed Lead Managers Shares (Millions) Price Low Price High Est. $ Volume Expected to Trade SCOOP Rating Rating Change
ERock, Inc. EROC Morgan Stanley/J.P. Morgan/Barclays/BofA Securities/Evercore ISI/Wolfe Nomura Alliance/BNP Paribas 27.9 21.50 21.50 $ 600.0 mil 6/10/2026 Priced S/O S/O
JAB Acquisition Corp. I JABU D. Boral Capital (ex-EF Hutton) 15.0 10.00 10.00 $ 150.0 mil 6/10/2026 Priced S/O S/O
Parabilis Medicines PBLS Leerink Partners/BofA Securities/Evercore ISI/Guggenheim Partners/LifeSci Capital 33.5 20.00 20.00 $ 670.0 mil 6/10/2026 Priced S/O S/O
Read more

Last 100 IPOs - June 9, 2026

Number of IPOs priced : 100
Number Up: 53
Number Down: 45
Number Unchanged: 2
Percentage Change From Issue Price: 7.68%
Percentage Change for The Nasdaq Composite 35.22%

2026 IPO Scorecard - June 9, 2026

Number of IPOs priced (Excluding 106 units) : 79
Number Up: 42
Number Down: 35
Number Unchanged: 2
Total Return From Issue Price: 6.89%
The Nasdaq Composite Index YTD % Change 35.22%